Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective.
Boon Piang CherKar Yee GanMohamed Ismail Abdul AzizLiang LinWilliam Ying Khee HwangLimei Michelle PoonKwong NgPublished in: Journal of medical economics (2020)
Our analysis showed tisagenlecleucel use in r/r DLBCL patients who failed at least 2 prior lines of systemic therapies was associated with exceedingly high ICER, which is unlikely to represent good use of healthcare resources. Comparative clinical evidence from the ongoing trials might provide more insight into future evaluations.